Original language | English (US) |
---|---|
Pages (from-to) | e323-e325 |
Journal | Journal of the European Academy of Dermatology and Venereology |
Volume | 36 |
Issue number | 5 |
DOIs | |
State | Published - May 2022 |
ASJC Scopus subject areas
- Infectious Diseases
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the European Academy of Dermatology and Venereology, Vol. 36, No. 5, 05.2022, p. e323-e325.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Telemedicine and dermatology hospital consultations during the COVID-19 pandemic
T2 - a multi-centre observational study on resource utilization and conversion to in-person consultations during the COVID-19 pandemic
AU - Trinidad, J.
AU - Gabel, C. K.
AU - Han, J. J.
AU - Bonomo, L.
AU - Cartron, A.
AU - Chand, S.
AU - Coburn, W.
AU - Daveluy, S.
AU - Davis, M.
AU - DeNiro, K. L.
AU - Guggina, L. M.
AU - Hennessy, K.
AU - Hoffman, M.
AU - Katz, K.
AU - Keller, J. J.
AU - Kim, S. J.
AU - Konda, S.
AU - Lake, E.
AU - Lincoln, F. N.
AU - Lo, J. A.
AU - Markova, A.
AU - Marvin, E. K.
AU - Micheletti, R. G.
AU - Newman, S.
AU - Nutan, F. N.U.
AU - Nguyen, C. V.
AU - Pahalyants, V.
AU - Patel, J.
AU - Rahnama-Moghadam, S.
AU - Rambhatla, P. V.
AU - Riegert, M.
AU - Reingold, R. E.
AU - Robinson, D. B.
AU - Rrapi, R.
AU - Sartori-Valinotti, J. C.
AU - Seminario-Vidal, L.
AU - Sharif-Sidi, Z.
AU - Smogorzewski, J.
AU - Spaccarelli, N.
AU - Stewart, J. R.
AU - Tuttle, S. D.
AU - Ulrich, M. N.
AU - Wanat, K. A.
AU - Di Xia, F.
AU - Kaffenberger, B.
AU - Kroshinsky, D.
N1 - Funding Information: Dr. John Trinidad holds leadership positions for JAAD, the Ohio Dermatological Association, and Congresional Policy Committee of the AAD. Dr. Eden Lake holds leadership positions for the Women's Dermatologic Society, JAAD, and Chicago Dermatologic Society. Dr. Alina Markova has led a Consultant/Advisory Role for Astrazeneca Pharmaceuticals LP and Alira Health and receives research funding from Incyte. Dr. Lucia Seminario‐Vidal has received grants/contracts from Eli Lilly, Soligenix, Helsinn, Eisai, Boehringer Ingelheim, Novartis, AbbVie, BMS, Celgene, Glenmark, Kyowa Kirin, Amgen, AnaptysBio, and Innate Pharma; has received consulting fees for Aptis Partners; has received payment from Helsinn and Kyowa Kirin; has participated in data or safety monitoring for Novartis, Boehringer Ingelheim, Helsinn, Kyowa Kirin, Regeneron, and Blueprint; and has held leadership positions for committees in the SDH and MDS. All other authors have no conflicts of interest to disclose.
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85123117037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123117037&partnerID=8YFLogxK
U2 - 10.1111/jdv.17898
DO - 10.1111/jdv.17898
M3 - Letter
C2 - 34932237
AN - SCOPUS:85123117037
SN - 0926-9959
VL - 36
SP - e323-e325
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 5
ER -